July 13, 2010

Dear Prescriber,

The New York State Medicaid Drug Utilization Review (DUR) Program retrospectively reviews the prescribing and dispensing of outpatient prescription medications in order to assure that prescriptions are appropriate, medically necessary, and are not likely to result in adverse medical outcomes. New York State Medicaid pharmacy claim data indicates that you have written prescription(s) for Vusion® (miconazole nitrate/zinc oxide/white petrolatum) ointment. Please consider the following information before prescribing Vusion®, as the DUR Program is concerned that there may be utilization of this medication that is not consistent with FDA approved labeling.

Documentation in the FDA approved labeling for Vusion® (miconazole nitrate/zinc oxide/white petrolatum) states ¹:

- Indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis in pediatric patients.
- Should not be used to prevent the occurrence of diaper dermatitis due to the potential for development of drug resistance (labeling for this product also warns against preventive use for diaper dermatitis in adult institutional settings).
- Should not be used longer than 7 days, as the safety of this medication when used for longer than 7 days is not known.

Recommended treatment options from the American Academy of Dermatology ² for recurrent diaper rash include:

- Changing diapers frequently.
- Using a warm washcloth instead of pre-moistened wipes.
- Applying a barrier cream with zinc oxide and keeping the diaper area open to the air as long as possible before putting on a clean diaper.

Zinc oxide and several cost-effective over-the-counter and prescription antifungal agents are available through the Medicaid program. For a complete list of medications covered by the Medicaid program, please refer to the eMedNY site: [http://www.emedny.org/info/formfile.html](http://www.emedny.org/info/formfile.html)

Please consider clinical appropriateness and cost effectiveness when prescribing Vusion®. In presenting this information to you, the DUR Program recognizes that safe and effective pharmacotherapy depends on the assessment of the patient’s entire clinical profile. We ask that you consider the information provided regarding the treatment of diaper dermatitis in pediatric patients.

Thank you for your professional assistance in this matter.

Sincerely,

John F. Naioti, Jr., R.Ph.
DUR Program Manager

¹ Vusion [package insert] Princeton, NJ; Barrier Therapeutics, Inc.; April 2007